Menu
← Oncology Approval Tracker
FDA DECISION ·
Releuko
filgrastim-ayow · Kashiv BioSciences
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Filgrastim biosimilar for labeled oncology supportive uses including febrile-neutropenia risk reduction during myelosuppressive chemotherapy, recovery after AML chemotherapy, and neutropenia support after myeloablative therapy followed by bone marrow transplantation.
LAMPGEN ANALYSIS
Why it matters
The biosimilar expands availability of short-acting growth-factor products for established labeled settings.
What research teams should watch
Specify the product and track doses relative to the chemotherapy or transplant schedule.
PRIMARY RECORDS